This site will be intermittently unavailable for routine maintenance starting on Friday, June 21st at 9pm and lasting through Sunday June 23rd.



Neulasta® (pegfilgrastim) is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Read More